Skip to main content

Clinical Trial Results


Dr. Stefan Anker and Dr. C. Michael Gibson Discuss: EMPEROR-Preserved: effect of empagliflozin on cardiovascular death and heart failure hospitalizations in patients with heart failure with a preserved ejection fraction, with and without diabetes

Loader Loading…
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab


Disclosures: TBD